Caplacizumab, a nanobody that blocks VWF is currently being used for the treatments of adults with acquired thrombotic thrombocytopenic purpura (TTP) in preventing the development of potentially life threatening microvascular thrombosis. The gene discussed is VWF; the disease is thrombotic thrombocytopenic purpura.